Antigen-specific and polyclonal CD4+ lamina propria T-cell lines: phenotypic and functional characterization.

Surface phenotype and function of lamina propria CD4+ T cells have been evaluated. In addition, long-term, antigen-specific and polyclonal lamina propria CD4+ T-cell lines have been generated and characterized. Lamina propria CD4+ T cells represent approximately 30% of lamina propria lymphocytes and are responsive to a variety of T-cell mitogens, including anti-CD3, concanavalin A, phytohaemagglutinin and pokeweed mitogen. In each case, however, lamina propria T cells are less responsive to these mitogens than spleen T cells. Freshly isolated lamina propria T cells produce substantial amounts of interleukin-2 (IL-2), interleukin-4 (IL-4), gamma interferon and to a lesser extent interleukin-5 (IL-5). Antigen-specific lamina propria CD4+ T-cell lines were generated by orally immunizing animals with antigen (KLH) in conjunction with cholera toxin as an oral adjuvant. Polyclonal lamina propria CD4+ T-cell lines were generated from unimmunized animals using anti-CD3 as a polyclonal stimulus. Both antigen-specific and polyclonal CD4+ T-cell lines were Thy-1+, alpha beta TCR+ and CD8-. The antigen-specific CD4+ T-cell line when stimulated by anti-CD3 and PMA produces predominantly IL-2, IL-4 and gamma interferon, with very little IL-5. In contrast, the polyclonal CD4+ T-cell line when similarly stimulated produces predominantly IL-4 and IL-5, with very little IL-2 and no detectable gamma interferon. In summary, lamina propria CD4+ T cells have been evaluated and in vitro conditions have been determined for successful generation of lamina propria CD4+ T-cell lines.     

Identification and characterization of a human CD4 silencer

Using transgenic mice, we have identified a human CD4 silencer contained within a 484-bp fragment in the first intron of the CD4 gene. Further experiments have mapped a lineage-specific silencing activity to a region of 190 bp. This region contains two protein-binding sites detected by deoxyribonuclease I footprinting analyses. Tested in transient transfection assays, these two DNA elements showed significant silencing activity restricted to the CD8 phenotype. In CD4 cells, either no clear effect (FP I) or strong enhancing activity (FP II) was observed by transient transfection assays. Despite the lineage-specific activity of these two elements, electrophoretic mobility shift assays (EMSA) showed similar levels of protein binding to the silencer element FP I in CD4 and CD8 T cells. Base substitutions in the FP I fragment abolished the silencing activity in transfected CD8 cells as well as the protein binding in EMSA, suggesting an important role of this protein-DNA interaction in CD4 gene regulation.     

Comparative studies of isolated CD3: CD8, CD3: CD3, and monovalent CD3 binding on CD8+ T-cell activation: model of progressive T-cell receptor aggregation synergism.

The TCR and CD8 complexes of CD8+ T cells bind to different regions of MHC class I molecules and both play important roles in the response of the CD8+ T cells to Ag/MHC on APCs. In this report, we mimicked common MHC binding with an anti-CD3:anti-CD8 (CD3,8) BSMAB to isolate the effect of CD3: CD8 pairing, compared this with the effect of CD3: CD3 pairing by the parental bivalent anti-CD3 MAB, and with monovalent anti-CD3 binding by an anti-CD3: anti-CD4 (CD3,4) BSMAB. CD3: CD8 pairing induced an increase in cytosolic free [Ca2+] 1.5 to 3.0-fold greater than the increase induced by CD3: CD3 pairing whereas monovalent CD3 binding induced only 20%-30% of the increase. Postbinding receptor migration studies suggested that microaggregation increased from monovalent CD3 binding to CD3: CD3 pairing to CD3: CD8 pairing. Further studies revealed that progressively higher concentrations of antibodies were needed from CD3,8 to CD3,3 to CD3,4 to initiate the same degree of DNA synthesis. These results demonstrated that Ti/CD3 and CD8 can indeed be bridged by a single molecule. A model of direct CD8: CD3 synergism was raised as a possible explanation for the enhanced activation induced by CD3: CD8 pairing. The observed parallel between all three parameters and the number of TCRs that can be directly linked by the Abs raised a nonmutually exclusive model whereby CD3 binding induces activated TCR intermediaries (aTCRi) that progressively synergize with other adjacent aTCRis. In this model, this dominant inter-aTCRi synergism may be enhanced by the di- and multimeric CD8 alpha chains serving as aTCRi-aggregation foci.     

一株识别CD83单克隆抗体的研制及其生物学特性鉴定

目的:鼠抗人CD83功能性单克隆抗体(mAb)的研制及其生物学特性的鉴定.方法:以人CD83转基因细胞L929/CD83为免疫原,常规免疫6～8周龄的雌性BALB/c小鼠;采用B淋巴细胞融合技术,将免疫小鼠脾脏细胞与Sp2/0融合,以L929/CD83、293/CD83转基因细胞为抗体筛选阳性细胞,经免疫荧光标记分析对杂交瘤进行反复筛选和多次的克隆化培养;采用Ig类和亚类快速定性试纸法、染色体核型分析、竞争结合抑制试验、间接免疫荧光法、Western blot对mAb的生物学特性进行鉴定.结果:获得1株稳定分泌鼠抗人CD83mAb的杂交瘤细胞株(命名为9D8),该mAb能特异性地识别成熟的DC、活化的T细胞及肿瘤细胞株Daudi、8226表达的CD83分子,该mAb识别的位点不同于商品化抗人CD83mAb(HB15e).结论:成功地研制1株鼠抗人CD83mAb,识别位点与HB15e不同,为更好地研究该分子的功能提供良好的物质基础.     

Identification and functional characterization of mouse CD29 with a mAb

The ß1 integrin subfamily, alternatively called verylate activation antigen (VLA), has been implicated in variouscellular functions. In this study, we generated a mAb againstthe mouse ß1 subunit (CD29) to examine the functionalproperty of mouse VLA proteins. After immunization with affinity-purifiedmouse VLA-4 (4ß1), a hamster mAb, HMß1-1,was established by screening mAb that reacted with 4-negatlveneuroblastoma C1300. The antigen defined by HMß1-1was widely distributed in various mouse cell lines and HMß1-1immunoprecipitated a 110-120 kDa protein common to VLA-1 andVLA-6, indicating that HMß1-1 recognizes the ß1subunit of mouse integrins. We then examined the inhibitoryeffect of HMß1-1 on VLA-dependent cell adhesion andactivation. HMß1-1 blocked the adhesion of mouse tumorcell lines to extracellular matrix proteins including collagen,laminin and fibronectin. Moreover, splenic T cell proliferationinduced by anti-CD3 mAb and allogeneic mixed lymphocyte responsewere strongly inhibited by HMß1-1 in combination withan anti-LFA-1 mAb. We conclude that HMß1-1 reactivewith mouse CD29 can inhibit VLA-dependent cellular functionsand, thus, would be useful for studying the physiological roleof ß1 integrins in vivo.     

Splice variants of human FOXP3 are functional inhibitors of human CD4+ T-cell activation

FOXP3 has been identified as a key regulator of immune homeostasis. Mutations within the FOXP3 gene result in dysregulated CD4+ T-cell function and elevated cytokine production, leading to lymphoproliferative disease. FOXP3 expression in CD4+ T cells is primarily detected with the CD4+ CD25+ regulatory T-cell population. In humans the protein is detected as a doublet following immunoblot analysis. The lower band of the doublet has been identified as a splice isoform lacking a region corresponding to exon 2. The aim of this study was to investigate whether the splice variant form lacking exon 2 and a new novel splice variant lacking both exons 2 and 7, were functional inhibitors of CD4+ T-cell activation. The data generated showed that full-length FOXP3 and both splice variant forms of the protein were functional repressors of CD4+ T-cell activation.     

Do CD4 and CD8 control T-cell activation via a specific tyrosine protein kinase?

The CD4 and CD8 glycoproteins play an important role in T-cell activation by binding to major histocompatibility complex (MHC) class II or class I molecules, respectively, and stabilizing their interactions with the T-cell receptor-CD3 complex during antigen presentation. Recent evidence suggesting that the cytoplasmic domains of CD4 and CD8 are physically, and perhaps functionally, linked to the T-cell specific tyrosine protein kinase, p56lck, adds a new dimension to our current understanding of their physiological function. Based on these and other recent findings, Tomas Mustelin and Amnon Altman present a working hypothesis that defines a novel role for CD4 or CD8 in regulating T-cell activation, and perhaps other processes, such as thymic repertoire selection and human immunodeficiency virus (HIV)-induced immunosuppression.     

Intensification of a suppressive HAART regimen increases CD4 counts and decreases CD8+ T-cell activation

A significant proportion of HIV-1-infected individuals on suppressive HAART regimens do not reconstitute CD4 counts well. If viral reservoirs persist and impact on CD4 reconstitution in a percentage of cases then addition of another antiretroviral agent could further suppress these reservoirs resulting in enhanced CD4 recovery. To evaluate this possibility, we studied the effect of adding abacavir to a chronically suppressive NNRTI containing HAART regimen for 8 patients on their CD4 count and expression of activation markers. Over the first 24 weeks of intensification, CD4 counts increased significantly (p=0.028). This increase continued after a year in follow-up with a significant rate of change in CD4 T-cells of 0.959+/-1.27 per week. In addition, during intensification changes in the percentage of CD38+CD8+ T-cells over time were significantly negatively correlated with changes in CD4 cell number over time above increases predicted without intensification (r(2)=0.716, p=0.008). These data support the possibility that in certain cases where suboptimal CD4 reconstitution occurs that intensification of the regimen can impact immunologic parameters.     

CD26: a surface protease involved in T-cell activation

CD26 is a proteolytic enzyme (dipeptidylpeptidase IV) with a wide tissue distribution and a unique specificity. Recent developments indicate that CD26 is a multifunctional molecule that may have important functions in the immune system. Here, Bernhard Fleischer reviews the current knowledge of CD26 and discusses the possible functions of this molecule in T lymphocytes.     

Reflections on CD8 T-cell activation and memory

CD8 T cells contribute to clearance and long-term protection following acute infection with certain viruses, bacteria, and protozoa, and may play an important role in tumor immunity. Primary adaptive CD8 T-cell responses have been conceptually divided into four phases: activation, expansion, contraction, and memory. We summarize each phase of the response, and discuss recent advances in our understanding of the development and maintenance of CD8 T-cell memory.     

Phenotypic and functional characterization of a CD4(+) CD25(high) FOXP3(high) regulatory T-cell population in the dog

Relatively little is known about regulatory T (Treg) cells and their functional responses in dogs. We have used the cross-reactive anti-mouse/rat Foxp3 antibody clone FJK-16s to identify a population of canine CD4(+) FOXP3(high) T cells in both the peripheral blood (PB) and popliteal lymph node (LN). FOXP3(+) cells in both PB and LN yielded positive staining with the newly developed anti-murine/human Helios antibody clone 22F6, consistent with the notion that they were naturally occurring Treg cells. Stimulation of mononuclear cells of LN origin with concanavalin A (Con A) in vitro yielded increased proportions and median fluorescence intensity of FOXP3 expression by both CD4(+) and CD8(+) T cells. Removal of the Con A and continued culture disclosed a CD4(+) FOXP3(high) population, distinct from the CD4(+) FOXP3(intermediate) T cells; very few CD8(+) FOXP3(high) T cells were observed, though CD8(+) FOXP3(intermediate) cells were present in equal abundance to CD4(+) FOXP3(intermediate) cells. The CD4(+) FOXP3(high) T cells were thought to represent activated Treg cells, in contrast to the FOXP3(intermediate) cells, which were thought to be a more heterogeneous population comprising predominantly activated conventional T cells. Co-staining with interferon-γ (IFN-γ) supported this notion, because the FOXP3(high) T cells were almost exclusively IFN-γ(-) , whereas the FOXP3(intermediate) cells expressed a more heterogeneous IFN-γ phenotype. Following activation of mononuclear cells with Con A and interleukin-2, the 5% of CD4(+) T cells showing the highest CD25 expression (CD4(+) CD25(high) ) were enriched in cells expressing FOXP3. These cells were anergic in vitro, in contrast to the 20% of CD4(+) T cells with the lowest CD25 expression (CD4(+) CD25(-) ), which proliferated readily. The CD4(+) CD25(high) FOXP3(high) T cells were able to suppress the proliferation of responder CD4(+) T cells in vitro, in contrast to the CD4(+) CD25(-) cells, which showed no regulatory properties.     

CD4-mediated functional activation of human CD4+CD25+ regulatory T cells

Naturally occurring CD4(+)CD25(+)FoxP3(+) regulatory T cells (CD25(+) Tregs) constitute a specialized population of T cells that is essential for the maintenance of peripheral self-tolerance. The immune regulatory function of CD25(+) Tregs depends upon their activation. We found that anti-CD4 antibodies activate the suppressive function of human CD25(+) Tregs in a dose-dependent manner. We demonstrate that CD4-activated CD25(+) Tregs suppress the proliferation of CD4(+) and CD8(+) T cells, their IL-2 and IFN-gamma production as well as the capacity of CD8(+) T cells to re-express CD25. By contrast, anti-CD4 stimulation did not induce suppressive activity in conventional CD4(+) T cells. These results identify CD4 as a trigger for the suppressive function of CD25(+) Tregs and suggest a possible CD4-mediated exploitation of these cells.     

Identification and functional characterization of Bet protein as a negative regulator of BFV3026 replication

Foamy virus (FV) establishes persistent infection in the host without causing apparent disease. Besides the transactivator Tas protein, another auxiliary protein—Bet—has been reported in prototype foamy virus, equine foamy virus, and feline foamy virus. Here, we found the putative bbet gene in clone C74 from a cDNA library of bovine foamy virus strain 3026 (BFV3026) by comparison of gene localization, composition, and splicing features with other known bet genes. Subsequently, BBet protein was detected in BFV3026-infected cells by Western blot and immunofluorescence analyses. Analysis of the BBet mutant infectious clone (pBS-BFVdelBBet) revealed that BBet could inhibit BFV3026 replication. Consistent with this result, overexpression of BBet in Cf2Th cells reduced BFV replication by approximately threefold. Furthermore, virus replication levels similarly were reduced by approximately threefold in pBS-BFV-transfected and BFV3026-infected Cf2Th cells stably expressing BBet compared with control cells. After three passages, BFV3026 replicated more slowly in BBet-expressing cells. This study implicates BBet as a negative regulator of BFV replication and provides a resource for future studies on the function of this protein in the virus lifecycle.     

Glucocorticoid receptor activation reduces CD11b and CD49d levels on murine eosinophils: characterization and functional relevance

In vitro incubation of mouse blood eosinophils with dexamethasone (DEX) resulted in concentration- and time-dependent reduction in CD11b and CD49d cell-surface expression as detected by flow cytometry. This inhibitory effect ranged between 20 and 40% for both integrins, and it was not related to alteration of cell survival. DEX was maximally effective at 1 microM, and it was prevented by coaddition of the glucocorticoid receptor antagonist RU486 (mifepristone; 10 microM). Budesonide, hydrocortisone, and prednisolone, but not the sex steroids testosterone and progesterone, reduced CD11b and CD49d cell-surface expression to a similar extent. Subchronic treatment of mice with 1 mg/kg DEX again reduced both CD11b and CD49d expression on circulating eosinophils, without alterations in CD11b messenger RNA expression as assessed by polymerase chain reaction analysis. In contrast, membrane but not intracellular protein expression of either CD11b or CD49d was inhibited by eosinophil incubation with DEX in vitro; thus, an interference with exportation of these adhesion molecules to the cell surface is proposed as the mechanism of action of the glucocorticoid. Finally, steroid effects on integrin expression were linked to a reduced eosinophil function as indicated by a lower degree of cell chemotaxis after incubation with DEX, an effect which was again prevented by 10 microM RU486. These observations may explain part of the therapeutic efficacy displayed by glucocorticoid hormones in the clinical control of tissue eosinophilia in allergic disease conditions.     

The role of CD4 in T-cell activation: accessory molecule or co-receptor?

CD4 is an MHC class II binding protein found on T cells that recognize peptide fragments of protein antigens bound to MHC class II molecules. In this review, Charlie Janeway argues that CD4 is a physical component of the T-cell receptor, and that CD4 augments signalling via the receptor by about 100-fold. He proposes the term co-receptor to describe this molecule and its functional homologue, CD8.     

Expression and functional significance of CTLA-4, a negative regulator of T cell activation

The generation of an effective immune response involves antigen-specific T cell expansion and differentiation of effector function. T cell activation requires at least two distinct signals, including signaling via the antigen-specific T cell receptor (TCR) and a costimulatory pathway. Antigen stimulation of T cells can lead either to a productive immune response, characterized by proliferation, differentiation, clonal expansion and effector function, or, in the absence of an appropriate costimulation, to a state of long-lasting unresponsiveness, termed anergy. Anergic T cells fail to proliferate and secrete cytokines in response to secondary stimulation. The interaction between the costimulatory molecule CD28 on T cells and members of the B7 family on antigen-presenting cell results in upregulation of T cell proliferation and cytokine production and induces the expression of the anti-apoptotic protein Bcl-xl. Based of these findings, the two-signal requirement model for T cell activation is generally accepted today. The negative regulatory mechanisms during T cell activation are not well understood, but they are crucial for the maintainance of lymphocyte homeostasis. For several years the functional role of the enigmatic CD28 homologue cytotoxic T lymphocyte antigen-4 (CTLA-4) in T cell activation has been both obscure and controversial. CTLA-4 was initially supposed to provide a costimulatory signal in conjunction with TCR/CD3 signaling. Today we know that CD28 and CTLA-4 molecules may have diametrically opposed functions: signaling via CD28, in conjunctive with TCR, is required for T cell activation, while signaling via CTLA-4 is a negative signal that inhibits T cell proliferation. How the T cell integrates signals through the TCR/CD3 complex, CD28 and CTLA-4 to initiate, maintain and terminate antigen-specific immune response is in fact not fully clarified. In this review, we will focus on the emerging role of CTLA-4 as a negative regulator of T lymphocyte activation and its role in the dynamic interplay of activatory and inhibitory signals.     

T-cell activation by anti-idiotypic antibody: evidence for the internal image.

Human lymphoproliferative responses to a rabbit anti-idiotypic antibody (anti-Id TB71) and the corresponding mycobacterial protein antigen [38,000 molecular weight (MW)] have been investigated in a number of donors. It was found that responsiveness to anti-Id TB71 correlated with responder and non-responder (four subjects each) status to the 38,000 MW antigen. Furthermore, the induction of T-cell proliferation by both the 38,000 MW antigen and the anti-Id TB71 was dependent on accessory cells. When taken together with the concordance between the 38,000 MW antigen and anti-Id responsiveness, this implies that the 38,000 MW antigen and anti-Id TB71 stimulate related, or at least partially overlapping, repertoires of T cells. This was confirmed by the finding that cloned T cells reactive with the 38,000 MW antigen also proliferated in response to the anti-Id TB71. These observations are readily explained if the anti-idiotypic antibody contains an internal image of, and can therefore mimic, the antigen.     

Identification and characterization of a second CD4-like gene in teleost fish

In fish, T cell subdivision is not well studied, although CD8 and CD4 homologues have been reported. This study describes a second teleost CD4-like gene, CD4-like 2 (CD4L-2). Two rainbow trout copies of this gene were found, -2a and -2b, encoding molecules sharing 81% aa identity. The 2a/2b duplication may be related to tetraploid ancestry of salmonid fishes. In the Fugu genome CD4L-2 lies head to tail with an earlier reported, very different CD4-like gene [Suetake, H., Araki, K., Suzuki, Y., 2004. Cloning, expression, and characterization of fugu CD4, the first ectothermic animal CD4. Immunogenetics 56, 368-374], which was designated CD4L-1 in the present article. The flanking genes of the Fugu CD4L-1 and CD4L-2 are reminiscent of the genes surrounding CD4 and LAG-3 in mammals. However, neither synteny nor phylogenetic analysis could decide between CD4 and LAG-3 identity for the fish CD4L genes. CD4L-1 and CD4L-2 share a tyrosine protein kinase p56(lck) binding motif in the cytoplasmic tail with CD4 but not with LAG-3. Trout CD4L-2 expression is highest in the thymus, similar to mammalian and chicken CD4, whereas Fugu CD4L-1 expression was highest in the spleen. However, CD4L-2 encodes only two IG-like domains, whereas CD4L-1, CD4 and LAG-3 encode four. The CD4-like genes 1 and 2 in fish apparently went through an evolution different from that of LAG-3 and CD4 in higher vertebrates.